Compare · BDX vs MDAI
BDX vs MDAI
Side-by-side comparison of Becton Dickinson and Company (BDX) and Spectral AI Inc. (MDAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and MDAI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 1064.8x MDAI ($49.6M).
- BDX has been more active in the news (9 items in the past 4 weeks vs 7 for MDAI).
- BDX has more recent analyst coverage (25 ratings vs 1 for MDAI).
- Company
- Becton Dickinson and Company
- Spectral AI Inc.
- Price
- -
- -
- Market cap
- $52.78B
- $49.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 1
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest MDAI
- Spectral AI’s DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly
- Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System
- Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet
- Director Dimaio John Michael was granted 32,000 shares, increasing direct ownership by 1% to 2,922,847 units (SEC Form 4)
- SEC Form 4 filed by Spectral AI Inc.
- Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds
- Director Dimaio John Michael was granted 32,000 shares, increasing direct ownership by 1% to 2,830,847 units (SEC Form 4)
- Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference
- Spectral AI Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Dimaio John Michael was granted 32,000 shares, increasing direct ownership by 1% to 2,798,847 units (SEC Form 4)